107 related articles for article (PubMed ID: 23978989)
21. Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model.
Sonpavde G; Jian W; Liu H; Wu MF; Shen SS; Lerner SP
Urol Oncol; 2009; 27(4):391-9. PubMed ID: 18534874
[TBL] [Abstract][Full Text] [Related]
22. Triple combination of irradiation, chemotherapy (pemetrexed), and VEGFR inhibition (SU5416) in human endothelial and tumor cells.
Bischof M; Abdollahi A; Gong P; Stoffregen C; Lipson KE; Debus JU; Weber KJ; Huber PE
Int J Radiat Oncol Biol Phys; 2004 Nov; 60(4):1220-32. PubMed ID: 15519795
[TBL] [Abstract][Full Text] [Related]
23. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
24. Autophagy Inhibition Enhances Sunitinib Efficacy in Clear Cell Ovarian Carcinoma.
DeVorkin L; Hattersley M; Kim P; Ries J; Spowart J; Anglesio MS; Levi SM; Huntsman DG; Amaravadi RK; Winkler JD; Tinker AV; Lum JJ
Mol Cancer Res; 2017 Mar; 15(3):250-258. PubMed ID: 28184014
[TBL] [Abstract][Full Text] [Related]
25. Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts.
Cumashi A; Tinari N; Rossi C; Lattanzio R; Natoli C; Piantelli M; Iacobelli S
Cancer Lett; 2008 Nov; 270(2):229-33. PubMed ID: 18586384
[TBL] [Abstract][Full Text] [Related]
26. Synergistic efficacy of irinotecan and sunitinib combination in preclinical models of anaplastic thyroid cancer.
Di Desidero T; Antonelli A; Orlandi P; Ferrari SM; Fioravanti A; Alì G; Fontanini G; Basolo F; Francia G; Bocci G
Cancer Lett; 2017 Dec; 411():35-43. PubMed ID: 28964784
[TBL] [Abstract][Full Text] [Related]
27. Synergistic antitumor effect of NVP-BEZ235 and sunitinib on docetaxel-resistant human castration-resistant prostate cancer cells.
Park HS; Hong SK; Oh MM; Yoon CY; Jeong SJ; Byun SS; Cheon J; Lee SE; Moon du G
Anticancer Res; 2014 Jul; 34(7):3457-68. PubMed ID: 24982354
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of Galectin-1 Sensitizes HRAS-driven Tumor Growth to Rapamycin Treatment.
Michael JV; Wurtzel JG; Goldfinger LE
Anticancer Res; 2016 Oct; 36(10):5053-5061. PubMed ID: 27798864
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin.
Lamszus K; Brockmann MA; Eckerich C; Bohlen P; May C; Mangold U; Fillbrandt R; Westphal M
Clin Cancer Res; 2005 Jul; 11(13):4934-40. PubMed ID: 16000592
[TBL] [Abstract][Full Text] [Related]
30. Tyrosine kinase receptor inhibitor-targeted combined chemotherapy for metastatic bladder cancer.
Wu CL; Ping SY; Yu CP; Yu DS
Kaohsiung J Med Sci; 2012 Apr; 28(4):194-203. PubMed ID: 22453067
[TBL] [Abstract][Full Text] [Related]
31. Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy.
Blansfield JA; Caragacianu D; Alexander HR; Tangrea MA; Morita SY; Lorang D; Schafer P; Muller G; Stirling D; Royal RE; Libutti SK
Clin Cancer Res; 2008 Jan; 14(1):270-80. PubMed ID: 18172279
[TBL] [Abstract][Full Text] [Related]
32. Human glioblastoma and carcinoma xenograft tumors treated by combined radiation and imatinib (Gleevec).
Oertel S; Krempien R; Lindel K; Zabel A; Milker-Zabel S; Bischof M; Lipson KE; Peschke P; Debus J; Abdollahi A; Huber PE
Strahlenther Onkol; 2006 Jul; 182(7):400-7. PubMed ID: 16826359
[TBL] [Abstract][Full Text] [Related]
33. Simultaneous targeting of Src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration.
Bai L; Yang JC; Ok JH; Mack PC; Kung HJ; Evans CP
Int J Cancer; 2012 Jun; 130(11):2693-702. PubMed ID: 21792888
[TBL] [Abstract][Full Text] [Related]
34. The tyrosine kinase inhibitor E-3810 combined with paclitaxel inhibits the growth of advanced-stage triple-negative breast cancer xenografts.
Bello E; Taraboletti G; Colella G; Zucchetti M; Forestieri D; Licandro SA; Berndt A; Richter P; D'Incalci M; Cavalletti E; Giavazzi R; Camboni G; Damia G
Mol Cancer Ther; 2013 Feb; 12(2):131-40. PubMed ID: 23270924
[TBL] [Abstract][Full Text] [Related]
35. Successful combination of sunitinib and girentuximab in two renal cell carcinoma animal models: a rationale for combination treatment of patients with advanced RCC.
Oosterwijk-Wakka JC; de Weijert MC; Franssen GM; Leenders WP; van der Laak JA; Boerman OC; Mulders PF; Oosterwijk E
Neoplasia; 2015 Feb; 17(2):215-24. PubMed ID: 25748241
[TBL] [Abstract][Full Text] [Related]
36. Enhanced cancer therapy with the combination of EGFR and VEGFR-2 targeting in an orthotopic glioblastoma model.
Diao Y; Tian XH; Huang YL; Chen LK; Lin XN; Zhuang ZW
J Chemother; 2010 Dec; 22(6):407-12. PubMed ID: 21303749
[TBL] [Abstract][Full Text] [Related]
37. RhoB mediates antitumor synergy of combined ixabepilone and sunitinib in human ovarian serous cancer.
Vishnu P; Colon-Otero G; Kennedy GT; Marlow LA; Kennedy WP; Wu KJ; Santoso JT; Copland JA
Gynecol Oncol; 2012 Mar; 124(3):589-97. PubMed ID: 22115851
[TBL] [Abstract][Full Text] [Related]
38. Sunitinib effects on the radiation response of endothelial and breast tumor cells.
El Kaffas A; Al-Mahrouki A; Tran WT; Giles A; Czarnota GJ
Microvasc Res; 2014 Mar; 92():1-9. PubMed ID: 24215790
[TBL] [Abstract][Full Text] [Related]
39. Synergistic antitumor activity of ixabepilone (BMS-247550) plus bevacizumab in multiple in vivo tumor models.
Lee FY; Covello KL; Castaneda S; Hawken DR; Kan D; Lewin A; Wen ML; Ryseck RP; Fairchild CR; Fargnoli J; Kramer R
Clin Cancer Res; 2008 Dec; 14(24):8123-31. PubMed ID: 19088027
[TBL] [Abstract][Full Text] [Related]
40. In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems.
Romanelli S; Perego P; Pratesi G; Carenini N; Tortoreto M; Zunino F
Cancer Chemother Pharmacol; 1998; 41(5):385-90. PubMed ID: 9523734
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]